A Window Study of Ixazomib in Untreated Indolent B-NHL.

Trial Profile

A Window Study of Ixazomib in Untreated Indolent B-NHL.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Ixazomib (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Planned primary completion date changed from 1 Dec 2021 to 30 Dec 2021.
    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top